Investigating Pacira Pharmaceuticals, Inc.

PACIRA SHAREHOLDER ALERT: National Securities Law Firm Investigates Claims on Behalf of Shareholders

September 26, 2014
New York, New York

Tripp Levy PLLC, a leading national securities and shareholder rights law firm, is investigating claims on behalf of investors of Pacira Pharmaceuticals, Inc. (“Pacira” or the “Company”) (NASDAQ: PCRX).

On September 25, 2014, the Company announced that it received a Warning Letter from the U.S. Food and Drug Administration’s (“FDA”) Office of Prescription Drug Promotion referencing certain promotional materials for EXPAREL® (bupivacaine liposome injectable suspension), an injectable drug that numbs post-surgical pain.

In the letter, the FDA said Pacira promotes its drug EXPAREL as being able to work for up to 72 hours when it has only been approved for 24-hour pain relief. “These claims overstate Exparel’s efficacy and are misleading,” the FDA said in the letter.

On this news, shares of Pacira fell $11.66 per share to $94.62, or more than 12%, on September 25, 2014.

If you purchased shares of Pacira, and wish to discuss this matter at no cost or expense, please contact us toll free at 1-800-511-7037 or contact us via our website.

Tripp Levy PLLC is a leading national securities and shareholder rights law firm with offices across the country representing both individual and institutional shareholders and, along with its affiliates, has recovered billions of dollars for shareholders. Tripp Levy PLLC is affiliated with Milberg LLP. Attorney advertising. Prior results do not indicate a similar outcome.


^